Genevation

H20

Description

Genevation is pioneering the use of artificial intelligence to transform personalized medicine and immunotherapy. Our proprietary Adapt AI platform integrates genomic, transcriptomic, and immunological data to accelerate the discovery of patient-specific neoantigens and the design of individualized cancer vaccines. By combining machine learning, immunogenomics, and systems biology, Genevation enables faster, more precise therapeutic development—reducing timelines from years to months. The company’s approach is being applied to oncology, infectious disease, and rare genetic disorders, with active collaborations spanning biotech, government, and academic sectors. Our mission is simple yet bold: to harness AI to make truly personalized therapies a clinical reality.